CHU de Lille — Lille

Public research footprint of CHU de Lille, compiled from the ClinicalTrials.gov public registry.

330

Registered studies

190

Active

121

Recruiting now

101

Completed

Stopped or withdrawn

Most-studied conditions

Relapsed or Refractory Multiple Myeloma (RRMM) · Leukemia, Lymphocytic, Chronic, B-Cell · Transitional Cell Cancer of Renal Pelvis and Ureter · Atherosclerotic Cardiovascular Disease (ASCVD)

Recently updated registry entries

NCT06820463 — A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab… (Recruiting)
NCT06571149 — Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and… (Recruiting)
NCT06220201 — A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in… (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at CHU de Lille?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 03, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.